The Remodulin generic patent case returns to New Jersey federal court for trial on Sandoz's contract liability, with no consumer payout. Remodulin is United Therapeutics' injectable treprostinil for pulmonary arterial hypertension, and the fight concerns generic treprostinil and related supply terms.
On Oct. 7, 2026, the Third Circuit reversed summary judgment for Sandoz on breach-of-contract liability. The court remanded that issue for trial, according to FindLaw's opinion summary.
Table of Contents
- What the Third Circuit decided
- Why patients cannot file a claim
- What the contract dispute covers
- What to do now
What the Third Circuit decided
The court split the case into contract and antitrust tracks. It revived the contract track for trial. It closed the antitrust track. The ruling vacated the Nov.
1, 2024 bench-trial award of about $61.6 million plus interest to Sandoz. Bloomberg Law reported the win as $70.6 million with interest in its award coverage. The same decision affirmed dismissal of federal antitrust claims and related state-law claims against United Therapeutics. The U.S. Court of Appeals ruling found valid procompetitive justifications for the company's conduct.
Why patients cannot file a claim
The only affected claimants are Sandoz and RareGen, now Liquidia PAH. Patients and general consumers are not parties to payment. Williams & Connolly notes this limit in its firm update.
The affirmed antitrust dismissal also closes treble damages, fees, and state antitrust recovery. Treble damages mean triple payment sometimes allowed in antitrust cases. That path is now closed in this dispute.
- Do not file a claim based on the remand.
- Ignore forms or ads promising a Remodulin consumer payout.
- Track only business-case updates if you follow generic drug pricing.
What the contract dispute covers
A Sept. 29, 2015 patent settlement gave Sandoz a license to sell generic treprostinil for subcutaneous and intravenous use. The court held the device, pump, and non-interference terms ambiguous. That ambiguity requires trial on what each side owed.
The dispute centered on injection cartridges for subcutaneous Remodulin. United Therapeutics paid to extend production after the supplier planned to stop. Sandoz sought a court order forcing sharing of cartridges and was denied, Williams & Connolly reports. Remodulin launched in 2002 for pulmonary arterial hypertension. Sandoz received FDA approval for generic injectable treprostinil in 2017, the Third Circuit opinion states.
What to do now
On Oct. 13, 2026, Liquidia announced a global settlement resolving all six suits with United Therapeutics. The deal keeps Yutrepia available for pulmonary arterial hypertension. It provides net $380.7 million to United Therapeutics and $10 million from United Therapeutics to resolve RareGen and Sandoz claims, according to Liquidia's settlement announcement. The remand may have little practical effect because of that later deal.
Business litigants sometimes settle trial issues after appeal. Consumers gain no filing step from either development. Ask your prescriber or pharmacy about current treprostinil options, supply, and coverage. Keep pharmacy receipts and explanation-of-benefits forms for any coverage appeal. Yutrepia remains available for pulmonary arterial hypertension under that later settlement.